Mitogen-activated protein kinase inhibitor PD98059 improves neuroimmune dysfunction in experimental autoimmune encephalomyelitis in SJL/J mice through the inhibition of nuclear factor-kappa B signaling in B cells

[1]  A. Nadeem,et al.  CC chemokine receptor 5 antagonist alleviates inflammation by regulating IFN-γ/IL-10 and STAT4/Smad3 signaling in a mouse model of autoimmune encephalomyelitis. , 2022, Cellular immunology.

[2]  A. Nadeem,et al.  CCR1 antagonist J-113863 corrects the imbalance of pro- and anti-inflammatory cytokines in a SJL/J mouse model of relapsing-remitting multiple sclerosis. , 2022, Immunobiology.

[3]  A. Nadeem,et al.  Acetyl-11-keto-β-boswellic acid improves clinical symptoms through modulation of Nrf2 and NF-κB pathways in SJL/J mouse model of experimental autoimmune encephalomyelitis. , 2022, International immunopharmacology.

[4]  A. Nadeem,et al.  CCR1 antagonist ameliorates experimental autoimmune encephalomyelitis by inhibition of Th9/Th22-related markers in the brain and periphery. , 2022, Molecular immunology.

[5]  A. Nadeem,et al.  Cathepsin B inhibitor alleviates Th1, Th17, and Th22 transcription factor signaling dysregulation in experimental autoimmune encephalomyelitis , 2022, Experimental Neurology.

[6]  Yuhong Yang,et al.  B cell depletion changes the immune cell profile in multiple sclerosis patients: One-year report , 2021, Journal of Neuroimmunology.

[7]  A. Nadeem,et al.  Pharmacological Inhibition of STAT3 by Stattic Ameliorates Clinical Symptoms and Reduces Autoinflammation in Myeloid, Lymphoid, and Neuronal Tissue Compartments in Relapsing–Remitting Model of Experimental Autoimmune Encephalomyelitis in SJL/J Mice , 2021, Pharmaceutics.

[8]  A. Nadeem,et al.  5-Aminoisoquinolinone, a PARP-1 Inhibitor, Ameliorates Immune Abnormalities through Upregulation of Anti-Inflammatory and Downregulation of Inflammatory Parameters in T Cells of BTBR Mouse Model of Autism , 2021, Brain sciences.

[9]  A. Nadeem,et al.  The MAP kinase inhibitor PD98059 reduces chromosomal instability in the autoimmune encephalomyelitis SJL/J-mouse model of multiple sclerosis. , 2021, Mutation research.

[10]  A. Nadeem,et al.  Methylmercury chloride exposure aggravates proinflammatory mediators and Notch-1 signaling in CD14+ and CD40+ cells and is associated with imbalance of neuroimmune function in BTBR T+ Itpr3tf/J mice. , 2020, Neurotoxicology.

[11]  M. Pender,et al.  Reduced IκB-α Protein Levels in Peripheral Blood Cells of Patients with Multiple Sclerosis—A Possible Cause of Constitutive NF-κB Activation , 2020, Journal of clinical medicine.

[12]  S. Zheng,et al.  Nuclear Factor κB (NF-κB)–Mediated Inflammation in Multiple Sclerosis , 2020, Frontiers in Immunology.

[13]  R. Palmiter,et al.  Interleukin-6 Derived from the Central Nervous System May Influence the Pathogenesis of Experimental Autoimmune Encephalomyelitis in a Cell-Dependent Manner , 2020, Cells.

[14]  Keiko Tanaka.  Autoimmune encephalomyelitis , 2019, Clinical and Experimental Neuroimmunology.

[15]  L. Wilkins.  The prevalence of MS in the United States , 2019, Neurology.

[16]  Shukun Zhang,et al.  Treatment with 3,4-dihydroxyphenylethyl alcohol glycoside ameliorates sepsis-induced ALI in mice by reducing inflammation and regulating M1 polarization. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[17]  C. Garlanda,et al.  Detrimental and protective action of microglial extracellular vesicles on myelin lesions: astrocyte involvement in remyelination failure , 2019, Acta Neuropathologica.

[18]  Jun Zhou,et al.  Regulation of NF-κB/MAPK signaling pathway attenuates the acute lung inflammation in Klebsiella pneumonia rats by mollugin treatment. , 2019, Microbial Pathogenesis.

[19]  G. Silberberg,et al.  MAPK pathway and B cells overactivation in multiple sclerosis revealed by phosphoproteomics and genomic analysis , 2019, Proceedings of the National Academy of Sciences.

[20]  G. Lal,et al.  The iNOS Activity During an Immune Response Controls the CNS Pathology in Experimental Autoimmune Encephalomyelitis , 2019, Front. Immunol..

[21]  Ruth Ann Marrie,et al.  The prevalence of MS in the United States , 2019, Neurology.

[22]  M. Prinz,et al.  Microglia in Central Nervous System Inflammation and Multiple Sclerosis Pathology. , 2019, Trends in molecular medicine.

[23]  M. Pender,et al.  Increased constitutive activation of NF-κB p65 (RelA) in peripheral blood cells of patients with progressive multiple sclerosis , 2018, Journal of Neuroimmunology.

[24]  A. Huber,et al.  GM-CSF Promotes Chronic Disability in Experimental Autoimmune Encephalomyelitis by Altering the Composition of Central Nervous System–Infiltrating Cells, but Is Dispensable for Disease Induction , 2018, The Journal of Immunology.

[25]  S. Miller,et al.  Targeting the GM-CSF receptor for the treatment of CNS autoimmunity. , 2017, Journal of autoimmunity.

[26]  A. Nadeem,et al.  Adenosine A2A receptor modulates neuroimmune function through Th17/retinoid-related orphan receptor gamma t (RORγt) signaling in a BTBR T+ Itpr3tf/J mouse model of autism. , 2017, Cellular signalling.

[27]  T. Toyoizumi,et al.  Faculty Opinions recommendation of Tumor necrosis factor-alpha mediates one component of competitive, experience-dependent plasticity in developing visual cortex. , 2017 .

[28]  S. Amor,et al.  Multiple sclerosis animal models: a clinical and histopathological perspective , 2017, Brain pathology.

[29]  Manoj Kumar,et al.  INGE GRUNDKE-IQBAL AWARD FOR ALZHEIMER’S RESEARCH: NEUROTOXIC REACTIVE ASTROCYTES ARE INDUCED BY ACTIVATED MICROGLIA , 2019, Alzheimer's & Dementia.

[30]  J. Hidalgo,et al.  Astrocytic IL-6 Influences the Clinical Symptoms of EAE in Mice , 2016, Brain sciences.

[31]  M. Menger,et al.  Deficiency of IκB Kinase β in Myeloid Cells Reduces Severity of Experimental Autoimmune Encephalomyelitis. , 2016, The American journal of pathology.

[32]  Jiyoun Lee,et al.  Discovery of a Small Molecule that Enhances Astrocytogenesis by Activation of STAT3, SMAD1/5/8, and ERK1/2 via Induction of Cytokines in Neural Stem Cells. , 2016, ACS chemical neuroscience.

[33]  Andrew B. Sholl,et al.  Simultaneous suppression of the MAP kinase and NF-κB pathways provides a robust therapeutic potential for thyroid cancer. , 2015, Cancer letters.

[34]  V. Rothhammer,et al.  Role of astrocytes and microglia in central nervous system inflammation , 2015, Seminars in Immunopathology.

[35]  Manuel A. Friese,et al.  Immunopathology of multiple sclerosis , 2015, Nature Reviews Immunology.

[36]  J. Grutzendler,et al.  Genetic variants associated with autoimmunity drive NFκB signaling and responses to inflammatory stimuli , 2015, Science Translational Medicine.

[37]  Deidre J. Devier,et al.  Increase in NF-κB-sensitive miRNA-146a and miRNA-155 in multiple sclerosis (MS) and pro-inflammatory neurodegeneration , 2015, Front. Mol. Neurosci..

[38]  B. Xiao,et al.  Fasudil mediates cell therapy of EAE by immunomodulating encephalomyelitic T cells and macrophages , 2015, European journal of immunology.

[39]  Klaus-Armin Nave,et al.  Oligodendrocytes: Myelination and Axonal Support. , 2015, Cold Spring Harbor perspectives in biology.

[40]  R. Pacheco,et al.  T-cell-mediated regulation of neuroinflammation involved in neurodegenerative diseases , 2014, Journal of Neuroinflammation.

[41]  Gregory F. Wu,et al.  B cell antigen presentation is sufficient to drive neuro-inflammation in an animal model of multiple sclerosis , 2014, Journal of Neuroimmunology.

[42]  A. Finkelsztejn.  Multiple Sclerosis: Overview of Disease-Modifying Agents , 2014, Perspectives in medicinal chemistry.

[43]  B. Becher,et al.  Multiple sclerosis-associated IL2RA polymorphism controls GM-CSF production in human TH cells , 2014, Nature Communications.

[44]  Amit Bar-Or,et al.  IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases , 2014, Nature.

[45]  S. Mahurkar,et al.  Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature. , 2014, Autoimmunity reviews.

[46]  M. Sahraian,et al.  Inhibitor IκBα promoter functional polymorphisms in patients with multiple sclerosis , 2014, Molecular Biology Reports.

[47]  M. Prinz,et al.  Nuclear factor kappa B (NF-κB) in multiple sclerosis pathology. , 2013, Trends in molecular medicine.

[48]  Guoqiang Chen,et al.  Preventive and Therapeutic Effects of Adenanthin on Experimental Autoimmune Encephalomyelitis by Inhibiting NF-κB Signaling , 2013, The Journal of Immunology.

[49]  D. Ron,et al.  Oligodendrocyte-Specific Activation of PERK Signaling Protects Mice against Experimental Autoimmune Encephalomyelitis , 2013, The Journal of Neuroscience.

[50]  F. Zipp,et al.  Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis. , 2013, Brain : a journal of neurology.

[51]  Agustina Garcı́a,et al.  Induction of atypical EAE mediated by transgenic production of IL‐6 in astrocytes in the absence of systemic IL‐6 , 2013, Glia.

[52]  M. Namaka,et al.  Elevation of Tumor Necrosis Factor Alpha in Dorsal Root Ganglia and Spinal Cord is Associated with Neuroimmune Modulation of Pain in an Animal Model of Multiple Sclerosis , 2013, Journal of Neuroimmune Pharmacology.

[53]  A. Suzumura,et al.  GM-CSF increases LPS-induced production of proinflammatory mediators via upregulation of TLR4 and CD14 in murine microglia , 2012, Journal of Neuroinflammation.

[54]  A. Quintana,et al.  Interleukin-6, a Major Cytokine in the Central Nervous System , 2012, International journal of biological sciences.

[55]  A. Fukamizu,et al.  Mechanism for p38α-mediated Experimental Autoimmune Encephalomyelitis* , 2012, The Journal of Biological Chemistry.

[56]  D. Gray,et al.  B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells , 2012, The Journal of experimental medicine.

[57]  D. Walker,et al.  Cobalt(II) β-ketoaminato complexes as novel inhibitors of neuroinflammation. , 2012, European journal of pharmacology.

[58]  Robert Weissert.  Experimental Autoimmune Encephalomyelitis , 2012 .

[59]  R. Gold,et al.  Constitutive activity of NF-kappa B in myeloid cells drives pathogenicity of monocytes and macrophages during autoimmune neuroinflammation , 2012, Journal of Neuroinflammation.

[60]  C. Constantinescu,et al.  Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS) , 2011, British journal of pharmacology.

[61]  Jiankun Cui,et al.  Pro-inflammatory cytokines and lipopolysaccharide induce changes in cell morphology, and upregulation of ERK1/2, iNOS and sPLA2-IIA expression in astrocytes and microglia , 2011, Journal of Neuroinflammation.

[62]  C. Teuscher,et al.  Activation of p38 MAPK in CD4 T cells controls IL-17 production and autoimmune encephalomyelitis. , 2011, Blood.

[63]  F. Safavi,et al.  The encephalitogenicity of TH17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF , 2011, Nature Immunology.

[64]  B. Becher,et al.  RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation , 2011, Nature Immunology.

[65]  A. Heimburg,et al.  PETIR-001, a dual inhibitor of dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN), ameliorates experimental autoimmune encephalomyelitis in SJL/J mice , 2011, Biological chemistry.

[66]  Istvan Pirko,et al.  The relevance of animal models in multiple sclerosis research. , 2011, Pathophysiology : the official journal of the International Society for Pathophysiology.

[67]  S. Moochhala,et al.  Substance P Upregulates Cyclooxygenase-2 and Prostaglandin E Metabolite by Activating ERK1/2 and NF-κB in a Mouse Model of Burn-Induced Remote Acute Lung Injury , 2010, The Journal of Immunology.

[68]  H. Weiner,et al.  Oral tolerance reduces Th17 cells as well as the overall inflammation in the central nervous system of EAE mice , 2010, Journal of Neuroimmunology.

[69]  D. Danilenko,et al.  B‐cell activation influences T‐cell polarization and outcome of anti‐CD20 B‐cell depletion in central nervous system autoimmunity , 2010, Annals of neurology.

[70]  T. Tedder,et al.  Regulatory B Cells (B10 Cells) and Regulatory T Cells Have Independent Roles in Controlling Experimental Autoimmune Encephalomyelitis Initiation and Late-Phase Immunopathogenesis , 2010, The Journal of Immunology.

[71]  Lawrence Steinman,et al.  T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis , 2010, Nature Medicine.

[72]  E. Mazzon,et al.  PD98059, a specific MAP kinase inhibitor, attenuates multiple organ dysfunction syndrome/failure (MODS) induced by zymosan in mice. , 2010, Pharmacological research.

[73]  F. Shi,et al.  B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis , 2010, Experimental Neurology.

[74]  C. Geis,et al.  Mild experimental autoimmune encephalitis as a tool to induce blood–brain barrier dysfunction , 2010, Journal of Neural Transmission.

[75]  E. Mazzon,et al.  Effect of PD98059, a Selective MAPK3/MAPK1 Inhibitor, on Acute Lung Injury in Mice , 2009, International journal of immunopathology and pharmacology.

[76]  Charles L. Raison,et al.  Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression , 2009, Biological Psychiatry.

[77]  B. Engelhardt,et al.  C-C chemokine receptor 6–regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE , 2009, Nature Immunology.

[78]  Irah L. King,et al.  Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. , 2009, Blood.

[79]  D. Centonze,et al.  Inflammation Triggers Synaptic Alteration and Degeneration in Experimental Autoimmune Encephalomyelitis , 2009, The Journal of Neuroscience.

[80]  S. McColl,et al.  Inhibition of CCR6 Function Reduces the Severity of Experimental Autoimmune Encephalomyelitis via Effects on the Priming Phase of the Immune Response1 , 2009, The Journal of Immunology.

[81]  B. Engelhardt,et al.  IL-6 transsignalling modulates the early effector phase of EAE and targets the blood-brain barrier , 2008, Journal of Neuroimmunology.

[82]  J. Greer,et al.  NF-kappa B, a potential therapeutic target for the treatment of multiple sclerosis. , 2008, CNS & neurological disorders drug targets.

[83]  D. Bourdette,et al.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis , 2008, Current neurology and neuroscience reports.

[84]  M. Fujimoto,et al.  Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. , 2008, The Journal of clinical investigation.

[85]  J. Hamilton.  Colony-stimulating factors in inflammation and autoimmunity , 2008, Nature Reviews Immunology.

[86]  Michael P. Stryker,et al.  Report Tumor Necrosis Factor-a Mediates One Component of Competitive, Experience-dependent Plasticity in Developing Visual Cortex , 2022 .

[87]  E. Mazzon,et al.  Evidence for the Role of Mitogen-Activated Protein Kinase Signaling Pathways in the Development of Spinal Cord Injury , 2008, Journal of Pharmacology and Experimental Therapeutics.

[88]  D. Arnold,et al.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. , 2008, The New England journal of medicine.

[89]  H. Link,et al.  IL-12/IFN-gamma/NO axis plays critical role in development of Th1-mediated experimental autoimmune encephalomyelitis. , 2008, Molecular immunology.

[90]  D. Willenborg,et al.  The contribution of nitric oxide and interferon gamma to the regulation of the neuro-inflammation in experimental autoimmune encephalomyelitis , 2007, Journal of Neuroimmunology.

[91]  E. Ponomarev,et al.  GM-CSF Production by Autoreactive T Cells Is Required for the Activation of Microglial Cells and the Onset of Experimental Autoimmune Encephalomyelitis1 , 2007, The Journal of Immunology.

[92]  濱野 公一,et al.  c-Jun N-terminal kinase 抑制による大動脈瘤薬物治療 , 2006 .

[93]  Bernhard Hemmer,et al.  Immunopathogenesis and immunotherapy of multiple sclerosis , 2006, Nature Clinical Practice Neurology.

[94]  B. Engelhardt,et al.  The LPS Receptor, CD14 in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis , 2006, Cellular Physiology and Biochemistry.

[95]  R. Malenka,et al.  Differential Regulation of AMPA Receptor and GABA Receptor Trafficking by Tumor Necrosis Factor-α , 2005, The Journal of Neuroscience.

[96]  H. Lassmann,et al.  Mitochondrial damage and histotoxic hypoxia: a pathway of tissue injury in inflammatory brain disease? , 2005, Acta Neuropathologica.

[97]  B. Uitdehaag,et al.  A randomized, double-blind, placebo-controlled pilot study of IV immune globulins in combination with IV methylprednisolone in the treatment of relapses in patients with MS , 2004, Multiple sclerosis.

[98]  J. Medina,et al.  Mitochondrial extracellular signal‐regulated kinases 1/2 (ERK1/2) are modulated during brain development , 2004, Journal of neurochemistry.

[99]  A. Sadovnick,et al.  Genetics of multiple sclerosis. , 1997, Human molecular genetics.

[100]  K. Jeng,et al.  c-Jun N-terminal kinase and, to a lesser extent, p38 mitogen-activated protein kinase regulate inducible nitric oxide synthase expression in hyaluronan fragments-stimulated BV-2 microglia , 2004, Journal of Neuroimmunology.

[101]  K. Ishii,et al.  The LPS receptor (CD14) links innate immunity with Alzheimer's disease , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[102]  N. Ruddle,et al.  Rat and Human Myelin Oligodendrocyte Glycoproteins Induce Experimental Autoimmune Encephalomyelitis by Different Mechanisms in C57BL/6 Mice1 , 2003, Journal of Immunology.

[103]  T. Olsson,et al.  Nitric oxide metabolite determinations reveal continuous inflammation in multiple sclerosis , 2003, Journal of Neuroimmunology.

[104]  G. Johnson,et al.  Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases , 2002, Science.

[105]  V. Calabrese,et al.  Nitric oxide synthase is present in the cerebrospinal fluid of patients with active multiple sclerosis and is associated with increases in cerebrospinal fluid protein nitrotyrosine and S‐nitrosothiols and with changes in glutathione levels , 2002, Journal of neuroscience research.

[106]  D. Feinstein,et al.  The Clinical Course of Experimental Autoimmune Encephalomyelitis is Associated with a Profound and Sustained Transcriptional Activation of the Genes Encoding Toll‐like Receptor 2 and CD14 in the Mouse CNS , 2002, Brain pathology.

[107]  C. Brosnan,et al.  Interferon‐β activates multiple signaling cascades in primary human microglia , 2002 .

[108]  Jorge R. Oksenberg,et al.  Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis , 2002, Nature Medicine.

[109]  Wade Morishita,et al.  Control of Synaptic Strength by Glial TNFα , 2002, Science.

[110]  Huitu Liu,et al.  MAPK signal pathways in the regulation of cell proliferation in mammalian cells , 2002, Cell Research.

[111]  C. Brosnan,et al.  Interferon-beta activates multiple signaling cascades in primary human microglia. , 2002, Journal of neurochemistry.

[112]  F. Lovicu,et al.  FGF-induced lens cell proliferation and differentiation is dependent on MAPK (ERK1/2) signalling. , 2001, Development.

[113]  J. McQualter,et al.  Granulocyte Macrophage Colony-Stimulating Factor A New Putative Therapeutic Target in Multiple Sclerosis , 2001 .

[114]  J. Avruch,et al.  Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. , 2001, Physiological reviews.

[115]  D. Feinstein,et al.  Expression and function of inducible nitric oxide synthase in neurons , 2001, Journal of Neuroimmunology.

[116]  M. Karin,et al.  Mammalian MAP kinase signalling cascades , 2001, Nature.

[117]  W. Brück,et al.  Interleukin-6 expression in human multiple sclerosis lesions , 2000, Neuroscience Letters.

[118]  D. Grzybicki,et al.  Interleukin 6 promotes vasculogenesis of murine brain microvessel endothelial cells. , 2000, Cytokine.

[119]  M. Pittenger,et al.  Adult Human Mesenchymal Stem Cell Differentiation to the Osteogenic or Adipogenic Lineage Is Regulated by Mitogen-activated Protein Kinase* , 2000, The Journal of Biological Chemistry.

[120]  Y. Saeki,et al.  IL-6 plays a crucial role in the induction phase of myelin oligodendrocyte glycoprotein 35–55 induced experimental autoimmune encephalomyelitis , 1999, Journal of Neuroimmunology.

[121]  G. Moretto,et al.  Activation of NF-kappaB and c-jun transcription factors in multiple sclerosis lesions. Implications for oligodendrocyte pathology. , 1999, The American journal of pathology.

[122]  S. Hauser,et al.  Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: A case for antigen‐specific antibody mediation , 1999, Annals of neurology.

[123]  S. Kassis,et al.  p38 mitogen-activated protein kinase inhibitors--mechanisms and therapeutic potentials. , 1999, Pharmacology & therapeutics.

[124]  S. Hauser,et al.  Identification of autoantibodies associated with myelin damage in multiple sclerosis , 1999, Nature Medicine.

[125]  V. Provitera,et al.  Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis: a correlation with clinical activity. , 1998, Immunopharmacology and immunotoxicology.

[126]  D. T. Dudley,et al.  PD98059 is an equipotent antagonist of the aryl hydrocarbon receptor and inhibitor of mitogen-activated protein kinase kinase. , 1998, Molecular pharmacology.

[127]  John C. Lee,et al.  Extracellular Signal-Regulated Kinase and p38 Subgroups of Mitogen-Activated Protein Kinases Regulate Inducible Nitric Oxide Synthase and Tumor Necrosis Factor-α Gene Expression in Endotoxin-Stimulated Primary Glial Cultures , 1998, The Journal of Neuroscience.

[128]  T. Owens,et al.  Astrocytes and microglia express inducible nitric oxide synthase in mice with experimental allergic encephalomyelitis , 1997, Journal of Neuroimmunology.

[129]  A. Bridges,et al.  A synthetic inhibitor of the mitogen-activated protein kinase cascade. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[130]  B. Scallon,et al.  Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor‐immunoglobulin fusion proteins , 1994, European journal of immunology.

[131]  P. Carrieri,et al.  Markers of activated T lymphocytes and T cell receptor gamma/delta+ in patients with multiple sclerosis. , 1993, European neurology.

[132]  P. Cohen,et al.  Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells. Comparison of the effects of nerve growth factor and epidermal growth factor. , 1992, The Biochemical journal.